文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

同步免疫检查点抑制剂与立体定向放射外科治疗非小细胞肺癌、黑色素瘤和肾细胞癌脑转移

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-12-05

该回顾性研究纳入2010至2016年接受立体定向放射外科-放疗(SRS-SRT)的260例非小细胞肺癌、黑色素瘤和肾细胞癌脑转移患者,其中79例联合免疫检查点抑制剂(ICI),35%为同步ICI。同步ICI未增加免疫相关不良事件或急性神经毒性,并预测减少≥3个新发脑转移(P=.045;OR=0.337)。同步ICI组中位总生存为24.7个月,优于单独SRS-SRT的12.9个月(P=.002;HR=2.69)和非同步联合的14.5个月(P=.006;HR=2.40)。

要点

  • 同步ICI未增加免疫相关不良事件或急性神经毒性。
  • 同步ICI预测减少≥3个新发脑转移(P=.045;OR=0.337)。
  • 同步ICI组中位OS为24.7个月,优于单独SRS-SRT的12.9个月(P=.002;HR=2.69)。

核心结论

  • SRS-SRT同步ICI可能降低新发脑转移发生率并改善生存,且不增加不良事件。

研究设计与样本

  • 回顾性研究纳入2010至2016年接受SRS-SRT的260例非小细胞肺癌、黑色素瘤和肾细胞癌脑转移患者,共治疗623个脑转移灶。
  • 患者分为单独SRS-SRT组(181例)、非同步ICI联合组和同步ICI联合组(79例中35%为同步)。
  • 同步ICI定义为SRS-SRT前后2周内给予ICI。

主要发现

  • 同步ICI未增加免疫相关不良事件或急性神经毒性。
  • 同步ICI预测减少≥3个新发脑转移(P=.045;OR=0.337)。
  • 单独SRS-SRT、非同步联合、同步联合组中位OS分别为12.9、14.5、24.7个月。
  • 多因素分析中同步ICI较单独SRS-SRT改善OS(P=.002;HR=2.69),较非同步联合也改善OS(P=.006;HR=2.40)。
  • 同步ICI的OS获益在ICI前(P=.002;HR=3.82)和ICI后(P=.021;HR=2.64)SRS-SRT亚组中均显著。

临床怎么用

  • 对于非小细胞肺癌、黑色素瘤和肾细胞癌脑转移患者,可考虑SRS-SRT同步ICI以改善生存并减少新发脑转移。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 同步ICI定义限于SRS-SRT前后2周内。
  • 排除活动性或未报告临床试验中接受ICI的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize the effect of concurrent stereotactic radiosurgery-stereotactic radiation therapy (SRS-SRT) and immune checkpoint inhibitors on patient outcomes and safety in patients with brain metastases (BMs). METHODS AND MATERIALS: We retrospectively identified metastatic non-small cell lung cancer, melanoma, and renal cell carcinoma patients who had BMs treated with SRS-SRT from 2010 to 2016 without prior whole-brain radiation therapy. We included SRS-SRT patients who were treated with anti-cytotoxic T-lymphocyte-associated protein 4 (ipilimumab) and anti-programmed cell death protein 1 receptor (nivolumab, pembrolizumab). Patients who were given immune checkpoint inhibitors on active or unreported clinical trials were excluded, and concurrent immune checkpoint inhibition (ICI) was defined as ICI given within 2 weeks of SRS-SRT. Patients were managed with SRS-SRT, SRS-SRT with nonconcurrent ICI, or SRS-SRT with concurrent ICI. Progression-free survival and overall survival (OS) were estimated using Kaplan-Meier survival curves, and Cox proportional hazards models were used for multivariate analysis. Logistic regression was used to identify predictors of acute neurologic toxicity, immune-related adverse events, and new BMs. RESULTS: A total of 260 patients were treated with SRS-SRT to 623 BMs. Of these patients, 181 were treated with SRS-SRT alone, whereas 79 received SRS-SRT and ICI, 35% of whom were treated with concurrent SRS-SRT and ICI. Concurrent ICI was not associated with increased rates of immune-related adverse events or acute neurologic toxicity and predicted for a decreased likelihood of the development of ≥3 new BMs after SRS-SRT (P=.045; odds ratio, 0.337). Median OS for patients treated with SRS-SRT, SRS-SRT with nonconcurrent ICI, and SRS-SRT with concurrent ICI was 12.9 months, 14.5 months, and 24.7 months, respectively. SRS-SRT with concurrent ICI was associated with improved OS compared with SRS-SRT alone (P=.002; hazard ratio [HR], 2.69) and compared with nonconcurrent SRS-SRT and ICI (P=.006; HR, 2.40) on multivariate analysis. The OS benefit of concurrent SRS-SRT and ICI was significant in comparison with patients treated with SRS-SRT before ICI (P=.002; HR, 3.82) or after ICI (P=.021; HR, 2.64). CONCLUSIONS: Delivering SRS-SRT with concurrent ICI may be associated with a decreased incidence of new BMs and favorable survival outcomes without increased rates of adverse events.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Chen L, Douglass J, Kleinberg L, et al. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2017. PMID: 29485071. doi:10.1016/j.ijrobp.2017.11.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。